"The Termeer Fellowship has been a transformative experience for me, both professionally and personally. It offered me the chance to learn from my peers, mentors, foundation members, and the numerous resources provided throughout the program. Most importantly, I have found a community." - Safia K. Rizvi, CEO of CILA THERAPEUTICS and 2023 Termeer Fellow. As we gear up to open the application for the Termeer Fellowship Class of 2025, we invite visionary, first-time CEOs, like Safia, to join a prestigious community committed to leadership excellence in biotechnology. Benefit from values-driven programming, personalized mentorship from industry leaders, and a diverse, global network. Mark your calendar: The application opens on September 30. This is your opportunity to advance your leadership abilities and grow your network as you transform your vision into impactful solutions for unmet medical needs and grow as a transformative leader in healthcare. Apply or share this incredible opportunity within your networks and help us create a future where every patient has a cure. To learn more about the Termeer Fellowship program, visit https://lnkd.in/e3D67eVU. #leadership #STEM #TermeerFoundation #HealthcareInnovation #RareDisease #Biotech #Bio #Biotechnology #PatientCare #LifeScience #PeopleEmpoweringCures #ConnectionsEmpoweringCures #LeadershipMatters #Healthcare #Mentorship #Mentor #Science #Leader #CEO #Founder #TermeerFellows
CILA THERAPEUTICS
生物技术研究
Boston，Massachusetts 306 位关注者
CILA THERAPEUTICS is dedicated to respiratory health and innovative treatments to help patients breathe easily
关于我们
CILA THERAPEUTICS is dedicated to respiratory health and focused on innovative treatments to help patients breathe easily and protect their lungs from irreversible damage. We own 100% of the robust IP portfolio that will generate value for investors and patients through the development of: 1. First-in-class, novel, inhaled therapeutics (de-risked) for the treatment of Airway Obstructive Pulmonary Diseases (AOPD) including COPD, Bronchiectasis, severe Asthma, Cystic fibrosis, and more to address a critical unmet need for ~20 million patients in the US and > 200 million globally. Our lead candidate CIL-05 can enter clinical studies in 12 months for our first indication, Primary Ciliary Dyskinesia (PCD), an orphan genetic disease. The path to approval is clearly defined after pre-IND meetings with the FDA. 2. A co-therapy platform to improve the transfection efficiency of nucleic acid therapeutics (RNA, DNA) and enhance delivery to lung and airway cells, increasing the efficacy and safety of these therapeutics for lung diseases, including Lung Cancer and Pulmonary Fibrosis CILA’s team has a successful track record with broad and diverse experience in patient care, drug discovery, development, manufacturing, commercialization, and reimbursement. The team is well-equipped to navigate drug development challenges and bring innovative therapies to market, positioning CILA Therapeutics as a leader in respiratory medicine.
- 网站
-
https://www.cilatx.com/
CILA THERAPEUTICS的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
- 创立
- 2020
- 领域
- Respiratory Rare Disease、Primary Ciliary Dyskinesia、Anti-viral、COPD、Severe Asthma、Bronchiectasis、Cystic Fibrosis、AntiOxidant、Airway obstructive diseases、Oligonucleotide、mRNA、DNA和Therapeutics
地点
-
主要
获取路线
US，Massachusetts，Boston
CILA THERAPEUTICS员工
动态
-
Founder & CEO of OMNISTARR - A Healthcare & IT Workforce Solution Company || Charter Member of TIE Boston || Honored Listee of Marquis Who's Who of America
What an exhilarating experience at the TiE Boston Women’s Pitch Competition and meeting the brilliant winners who showcased their exceptional talent and entrepreneurial spirit. Witnessing your groundbreaking innovations in creating impactful solutions in healthcare is truly the future of what is to come. A special shoutout to the winners Irena King, Surgicure Technologies, Inc., Ananya Zutshi, Guardian Bio, Rachel Zayas-Schwartz, AGED Diagnostics for not only pushing the boundaries of what's possible but also having the vision and dedication to see your trailblazing ideas come to fruition. Congratulations to each of you for your well-deserved success! Kudos to all the participants on bringing forth and presenting your innovations Safia K. Rizvi, CILA THERAPEUTICS, Sarah Ostadabbas, AiWover, Rashmi Agrawal, CipherSonic Labs Inc., Christy Fernandez-Cull, PhD, MBA, Davinci Wearables To the esteemed jury members, Ann DeWitt, Sangeeta Moorjani, Stacey Messier, Pratima Abichandani, it was great to meet and interact with you! Thank you for sharing your expertise and bringing on board a wealth of experience and insight. And as always, TiE Boston, we trust in your unwavering commitment to continue to encourage the entrepreneurial spirit within our community. At OMNISTARR, we believe in boosting these visionary leaders and fostering a community where groundbreaking ideas can thrive are crucial. Empowering the frontline in healthcare and equipping them with the tools, know how is where we believe the future in health care lies. Purnanand Sarma #PowerWomen #TiEBoston #WomenInBusiness #Entrepreneurship #Innovation #Omnistarr #Leadership #Congratulations
-
-
??Celebrating Excellence in Leadership: Safia K. Rizvi CEO of CILA THERAPEUTICS Recognized as One of the "50 Women to Watch for Corporate Boards" Congratulations to Safia on being honored as one of the 50/50 Women on Boards Women to Watch for Corporate Boards. Chosen from a pool of nearly 1,000 talented applicants, this recognition is a testament to her exceptional leadership, dedication, and unwavering commitment to driving positive change in the corporate world and healthcare industry. Safia's visionary approach and strategic mindset have consistently set her apart as a leader who excels in her professional endeavors and inspires many women in science and technology. She has significantly contributed to science and industry across the globe, and this accolade is a well-deserved acknowledgment of her hard work, perseverance and relentless pursuit of excellence. Read more below ? https://lnkd.in/emehAdcu #Leadership #CorporateBoards #WomenInBusiness #Inspiration #Achievement #Congratulations #PulmonaryHealth #LungDisease #Innovation #cilatherapeutics
-
CILA THERAPEUTICS CEO Safia K. Rizvi to participate as a delegate of The Termeer Foundation at the Netherlands Innovation Network in Boston investor conference in Rotterdam. Read more below ?? https://lnkd.in/g2n9wgAs
?? BOS ?? ?? AMS ?? RTM We are so thrilled to be back in the Netherlands - this time with The Termeer Foundation delegation! After landing at Schiphol, the delegation made their way to Rotterdam, which is where they will call their 'homebase' for the week ahead. ?? Jam-packed with site visits, in-depth discussions with industry and government partners about seeking the 'life' in life sciences and remembering our mission in health is one centered around patients, this week will take the delegates from Rotterdam to the Hague to Leiden, Utecht and beyond. They will end their week at the Global Investor's Forum at Innovation for Health - the Netherlands' premier conference for innovators in Life Sciences and Health. Watch this space for updates on their busy week ahead! ?? Read on to meet the delegation of Termeer Fellows and other partners who are continuing to build, expand and deepen the relationship between Massachusetts and the Netherlands' life sciences innovation ecosystems! Delegation Leads: Belinda Termeer, Catharine Smith and Erica Mawby-Roche, The Termeer Foundation Delegates: Cinzia Silvestri, Bi/ond | Safia K. Rizvi, CILA THERAPEUTICS | Yael Weiss, Mahzi Therapeutics | Jeanne LeClair, Massachusetts Life Sciences Center | Freddy Nguyen, MD, PhD, Massachusetts Institute of Technology | Jeevan Ramapriya, MOITI Massachusetts Office of International Trade and Investment | Ana Maiques, Neuroelectrics | Minmin Yen, Ph.D., MPH (she/her), PhagePro | Kasper Roet, QurAlis | Claudine van der Sande, Rhythm Pharmaceuticals Inc. | June Park, Ph.D., siRNAgen Therapeutics | Daniel Fischer, Tevard Biosciences | Stan Wang, MD, PhD, Thymmune Therapeutics Organizers: Kim Tran, Netherlands Innovation Network in Boston | Maikel Walker and Simone Ho, Netherlands Enterprise Agency | Laura Duran, Health~Holland | Robbert Wever, hollandbio #LifeSciencesandHealth #InnovationMission #Netherlands #InnovationEcosystem #Massachusetts #InnovateForHealth #GlobalInvestorsForum